Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial

Keyphrases

• Antipsychotics 100%
• First-episode Psychosis 100%
• Metabolic Risk Factors 100%
• Naïve Patients 75%
• Antipsychotic-naïve 75%
• Hypertriglyceridemia 50%
• Haloperidol 50%
• Olanzapine 50%
• Ziprasidone 50%
• Amisulpride 50%
• Quetiapine 50%
• Hyperglycemia 50%
• First Episode 50%
• Prevalence Rate 50%
• Individual Risk Factors 50%
• Metabolic Syndrome Prevalence 50%
• Diabetes 25%
• Hypertension 25%
• Patients with Schizophrenia 25%
• Prior Exposure 25%
• Metabolic Syndrome 25%
• Treatment Group 25%
• Incidence Rate 25%
• Confounding Effect 25%
• Metabolic Abnormalities 25%
• Abdominal Obesity 25%
• Metabolic Changes 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Prevalence 100%
• Antipsychotic 100%
• Metabolic Syndrome X 60%
• Olanzapine 40%
• Ziprasidone 40%
• Quetiapine 40%
• Amisulpride 40%
• 4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol 40%
• Hyperglycemia 40%
• Hypertriglyceridemia 40%
• Abdominal Obesity 20%
• Antipsychotic Drug 20%
• Treatment Group 20%

Neuroscience

• Antipsychotic 100%
• Risk Factor 100%
• Ziprasidone 33%
• Olanzapine 33%
• Quetiapine 33%
• Amisulpride 33%
• Hyperglycemia 33%
• Haloperidol 33%